share_log

Retail Investors Who Hold 55% of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Gained 6.5%, Insiders Profited as Well

Retail Investors Who Hold 55% of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Gained 6.5%, Insiders Profited as Well

持有浙江佐力藥業股份有限公司(SZSE: 300181)55%股份的零售投資者獲得了6.5%的收益,內部人員也獲利了。
Simply Wall St ·  07/01 19:34

Key Insights

主要見解

  • Zhejiang Jolly PharmaceuticalLTD's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public
  • 43% of the business is held by the top 25 shareholders
  • Insider ownership in Zhejiang Jolly PharmaceuticalLTD is 24%
  • 浙江佐力藥業有限公司的大量零售投資者持股表明,關鍵決策受到更廣泛公衆股東的影響。
  • 前25名股東持有43%的業務。
  • 佐力藥業的內部持股比例爲24%。

A look at the shareholders of Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) can tell us which group is most powerful. The group holding the most number of shares in the company, around 55% to be precise, is retail investors. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

觀察佐力藥業股份有限公司(SZSE:300181)的股東信息,可以看出哪一組最爲強大。持有公司股份最多的群體,精確到約55%,是零售投資者。換句話說,該群體將從其對公司的投資中獲取最高回報(或最高虧損)。

Retail investors gained the most after market cap touched CN¥11b last week, while insiders who own 24% also benefitted.

上週市值達到110億元后,零售投資者獲得最多收益,持有24%的內部股東也獲益。

In the chart below, we zoom in on the different ownership groups of Zhejiang Jolly PharmaceuticalLTD.

在下圖中,我們放大了佐力藥業的不同所有權群體。

ownership-breakdown
SZSE:300181 Ownership Breakdown July 1st 2024
SZSE: 300181所有權細節於2024年7月1日

What Does The Institutional Ownership Tell Us About Zhejiang Jolly PharmaceuticalLTD?

機構投資者在佐力藥業有限公司擁有相當數量的股份。這表明公司在投資社區中具有一定的信譽度。然而,最好要警惕依賴機構投資者所帶來的所謂認證。他們也會犯錯。當多個機構持有一隻股票時,總會存在一種「擁擠的交易」風險。當這樣的交易出現問題時,多方可能會競相快速賣出股票。這種風險在一個沒有增長曆史的公司中更高。您可以看到佐力藥業有限公司的歷史收益和營業收入,但請記住,故事總是更復雜的。

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

許多機構衡量其業績的標準是一個近似於當地市場的指數。因此,他們通常更加關注包括在主要指數中的公司。

As you can see, institutional investors have a fair amount of stake in Zhejiang Jolly PharmaceuticalLTD. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Zhejiang Jolly PharmaceuticalLTD's historic earnings and revenue below, but keep in mind there's always more to the story.

正如您所見,機構投資者在佐力藥業有相當大的股份。 這可能表明該公司在投資社區中享有一定的信譽度。 但是,最好謹慎依賴所謂的來自機構投資者的驗證。 他們也會有時候判斷失誤。 當多家機構持有某股票時,總會存在它們陷入'擁擠交易'的風險。 當這種交易出現問題時,多方可能競相拋售股票。 這種風險在沒有增長曆史的公司中更高。 您可以看到佐力藥業的歷史收益和營業收入,但請記住故事總是更加複雜的。

earnings-and-revenue-growth
SZSE:300181 Earnings and Revenue Growth July 1st 2024
SZSE:300181 營業收入和收益增長 2024年7月1日

Hedge funds don't have many shares in Zhejiang Jolly PharmaceuticalLTD. Looking at our data, we can see that the largest shareholder is Youqiang Yu with 19% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 3.2% and 2.4%, of the shares outstanding, respectively.

對沖基金在佐力藥業有限公司中沒有太多股份。從我們的數據來看,最大的股東是俞友強,持有流通股的19%。同時,第二大和第三大股東分別持有該公司流通股的3.2%和2.4%。

Our studies suggest that the top 25 shareholders collectively control less than half of the company's shares, meaning that the company's shares are widely disseminated and there is no dominant shareholder.

我們的研究表明,前25大股東共控制了公司股份的不到一半,這意味着公司的股份廣泛分散,沒有主導股東。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There is a little analyst coverage of the stock, but not much. So there is room for it to gain more coverage.

儘管研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的推薦也是一個好禮。該股票受到的分析師覆蓋範圍很小,但不多。因此,它有更多的空間獲得更多的覆蓋範圍。

Insider Ownership Of Zhejiang Jolly PharmaceuticalLTD

佐力藥業的內部持股

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

在不同國家,內部人員的定義可能會略有不同,但董事會成員始終是內部人員。管理層最終向董事會負責。然而,如果管理人員是創始人或CEO,那麼成爲執行董事會成員也是很常見的。

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

大多數人認爲內部所有權是積極的,因爲它可以表示董事會與其他股東的利益相一致。但是,在某些場合下,這個團體的權力過於集中。

Our information suggests that insiders maintain a significant holding in Zhejiang Jolly Pharmaceutical Co.,LTD. It is very interesting to see that insiders have a meaningful CN¥2.7b stake in this CN¥11b business. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

我們的信息表明,內部人員在佐力藥業有限公司中持有大量股份。看到內部人員在這家110億元規模的公司中持有意義深遠的27億元股份,這非常有趣。大多數人會說,這表明了這家公司內外部員工的利益高度一致,特別是對於這樣一家公司來說。您可以單擊此處查看內部人員是否一直在購買或銷售。

General Public Ownership

一般大衆所有權

The general public, who are usually individual investors, hold a substantial 55% stake in Zhejiang Jolly PharmaceuticalLTD, suggesting it is a fairly popular stock. With this amount of ownership, retail investors can collectively play a role in decisions that affect shareholder returns, such as dividend policies and the appointment of directors. They can also exercise the power to vote on acquisitions or mergers that may not improve profitability.

普通大衆,通常是個人投資者,在佐力藥業有着相當大的55%股權,表明它是一隻相當受歡迎的股票。在這種所有權比例下,零售投資者可以共同參與影響股東回報的決策,比如股利政策和董事會任命。他們還可以行使投票權,對可能不利於盈利能力的收購或兼併進行表決。

Private Company Ownership

私有公司的所有權

We can see that Private Companies own 4.3%, of the shares on issue. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

我們可以看到,私人公司擁有發行股份的4.3%。私人公司可能是關聯方。有時,內部人員通過持有私人公司的股份而不是以個人身份持有公共公司的利益。雖然很難得出任何廣泛的結論,但值得注意的是這是一個需要進一步研究的領域。

Next Steps:

下一步:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Be aware that Zhejiang Jolly PharmaceuticalLTD is showing 1 warning sign in our investment analysis , you should know about...

我發現查看公司的真正所有者非常有趣。但要真正獲得洞察力,我們也需要考慮其他信息。要注意,佐力藥業公司在我們的投資分析中顯示了1個警示標誌,你應該知道……

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

如果您像我一樣,可能希望考慮這家公司是否會增長或縮小。幸運的是,您可以查看此免費報告,顯示分析師對其未來的預測。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,也可以發送電子郵件至editorial-team@simplywallst.com

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論